Stem Cell Society Challenges NIH Funding Pause Citing Risks to Major Clinical Breakthroughs

The ISSCR warns that NIH restrictions on embryonic stem cell research could derail Phase III trials for Parkinson’s and diabetes, risking billions in investment.

By: AXL Media

Published: Apr 25, 2026, 11:09 AM EDT

Source: Information for this report was sourced from EurekAlert

Scientific Community Rejects Federal Constraints on Stem Cell Access

The International Society for Stem Cell Research (ISSCR) has formally challenged a recent shift in policy by the National Institutes of Health (NIH). In a detailed response to a federal Request for Information, the global body expressed deep concern over the NIH’s decision to pause new submissions to the Human Embryonic Stem Cell (hESC) Registry. The society, which counts nearly 5,000 scientists and industry leaders among its members, argues that this administrative freeze and the proposed reduction in federal reliance on these cells could paralyze decades of medical advancement.

The Golden Standard for Modern Regenerative Medicine

Human embryonic stem cells are viewed by the scientific community as the definitive benchmark for pluripotency, possessing the unique ability to self-renew and transform into any cell type in the body. According to the ISSCR, these cells have been foundational to the modern understanding of human development and disease modeling. Decades of federal funding have established a sophisticated infrastructure of cell repositories and standardized protocols that now support a global research ecosystem. Without these specific materials, researchers warn that the accuracy and reproducibility of human-relevant drug discovery would be significantly diminished.

High Stakes for Late Stage Clinical Trials in the United States

The timing of the NIH policy shift is particularly sensitive as the field reaches what experts call a translational inflection point. As of late 2024, nearly half of all global clinical trials involving hESC-derived products were based in the United States. These include critical Phase III trials aimed at treating Parkinson’s disease, Type 1 diabetes, and drug-resistant epilepsy. The ISSCR warns that any disruption to the registry or funding streams could derail these programs just as they approach potential regulatory approval, effectively wasting billions of dollars in prior federal investment.